STERIS Continues To Expect As Reported Revenue From Continuing Operations To Increase 6.5-7.5% In Fiscal 2025; Adjusted EPS To Be In The Range Of $9.05-$9.25 Vs $9.14 Est.
STERIS Continues To Expect As Reported Revenue From Continuing Operations To Increase 6.5-7.5% In Fiscal 2025; Adjusted EPS To Be In The Range Of $9.05-$9.25 Vs $9.14 Est.
Fiscal 2025 Outlook Reiterated
For fiscal 2025, the Company continues to expect as reported revenue from continuing operations to increase 6.5-7.5%. Based on forward rates through March 31, 2025, currency is expected to be neutral to revenue in fiscal 2025. Constant currency organic revenue from continuing operations is anticipated to increase 6-7%. In April 2024, the Company completed a divestiture of its Controlled Environment Services business within the Life Sciences segment. Total annual revenue for this business in fiscal 2024 was approximately $35 million which will be excluded from constant currency organic revenue growth from continuing operations in fiscal 2025. Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25 compared with $8.20 in adjusted earnings from continuing operations in fiscal 2024. The fiscal 2025 outlook assumes an effective tax rate of approximately 23%. Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million.
2025财年展望重申
对于2025财年，公司预计持续营运业务的报告营业收入将增长6.5-7.5%。根据2025年3月31日的远期汇率，预计货币在2025财年对营业收入不产生影响。持续营运业务的不变汇率有机营业收入预计将增加6-7%。2024年4月，公司完成了在生命科学领域内受控环境服务业务的剥离。该业务在2024财年的总收入约为3500万美元，将在2025财年的不变汇率有机营业收入中被排除在外。持续营运业务的每股摊薄调整收益预计为$9.05至$9.25，相比于2024财年持续营运业务的调整收益$8.20。2025财年展望假设有效税率约为23%。预计资本支出将约为36000万美元，自由现金流预计约为70000万美元。